Introduction {#Sec1}
============

The major histocompatibility complex class I chain related A (MICA) and MICB molecules are ligands of NKG2D receptors on natural killer (NK) cells, gamma/delta T cells, NKT cells, and CD8aß T cells, and mediate antitumor immune responses by stimulating innate and adaptive immune surveillance \[[@CR1]--[@CR3]\]. Several polymorphisms have been reported for MICA and MICB coding and noncoding sequences, located within the MHC class I region close to the tumor necrosis factor gene \[[@CR4], [@CR5]\]. The MICA-TM microsatellite polymorphism is present in exon 5 with eight alleles (A4, A5, A5.1, A6, A7, A8, A9, and A10), while the MICB gene contains a microsatellite polymorphism named C1_2\_A in intron 1 comprising 16 alleles \[[@CR6], [@CR7]\]. Different MICA molecules were reported to vary in their affinities to soluble NKG2D receptors, which may influence antitumor immune responses \[[@CR5], [@CR8]\]. Recent studies have shown increased serum levels of soluble MICA molecules in patients with various malignancies with a correlation to advanced tumor stages \[[@CR9]\]. Circulating tumor-derived soluble MICA molecules induce downregulation of NKG2D receptors on natural killer cells and thereby decrease responsiveness of tumor-antigen-specific effector T cells \[[@CR10]\]. The mechanism of T and NK cell silencing by down regulation of NKGD cells induced by soluble ligands or chronic exposure to cell surface bound ligands may represent an important mechanism for tumor cells to escape host antitumor immune responses. Some reports have indicated associations of specific MICA alleles with epithelial tumors of the nasopharynx and gastric mucosa, with hematopoetic neoplasia and with chronic inflammatory and autoimmune disorders \[[@CR11]--[@CR15]\]. The allele and genotype frequencies of MICA-TM and MICB C1_2\_A microsatellite polymorphisms in patients with colorectal cancer and a possible immunogenetic predisposition for the development of colorectal cancer or tumor progression have not yet been investigated. We have therefore analyzed the MICA-TM and MICB C1_2\_A polymorphisms in samples of normal colon mucosa and tumor tissue from colorectal cancer patients in comparison to a cohort of healthy controls and investigated possible correlations to tumor characteristics and disease progression.

Methods {#Sec2}
=======

Patients and Controls {#Sec3}
---------------------

Seventy-nine patients with colorectal cancer were analyzed. The patients had been treated between Jan. 1998 and Dec. 2002 according to the principles of oncologic surgery, and tumors were classified according to TNM/UICC criteria following histopathological examination. Mean age was 67.4 ± 10.9 years (range, 34--88 years), 52.5% of the patients were male and 47.5% female. Sixty-eight patients had sporadic colorectal cancer. Patients with evidence for polyposis cancer syndromes were excluded from the study. Eleven patients with clinical evidence for hereditary nonpolyposis colon cancer according to Bethesda criteria were analyzed separately for microsatellite instability to investigate a possible correlation of the DNA replication error pathway with alterations in host antitumor immunity \[[@CR16]\]. Primary tumors were localized in the colon (*n* = 54) and rectum (*n* = 25). Twenty-three patients had UICC stage IV tumors with distant metastasis localized in the liver (*n* = 12), lungs (*n* = 6), peritoneum (*n* = 4), or at multiple sites (*n* = 4). Results of lymph node involvement (N-classification) were included in the study, when at least 12 lymph nodes were removed and histopathologically examined. Frequencies of MICA-TM and MICB C1_2\_A polymorphisms in colorectal cancer patients were compared to a previously analyzed cohort of healthy controls (*n* = 306) \[[@CR17]\]. The study was approved by the local ethics committee, and patients\' informed consent was obtained.

Postoperative follow-up was performed according to the recommendations of the Munich cancer center and prospectively documented in an institutional data base. Follow-up intervals were initially every 6 months for 2 years, then yearly for up to the sixth year and at 2-year intervals for up to 10 years, including clinical examination, determination of carcinoembryonic antigen levels, upper abdomen sonography, abdominal CT scan, and total colonoscopy. Rectoscopy was performed in patients with rectal cancer or with an anastomosis below 12 cm as measured from the anocutanous line. Only patients with complete histopathological examination according to the TNM/UICC criteria and prospective follow-up were considered for analysis of survival times. Mean follow-up ±SD was 56.2 ± 36.3 months (range, 1--106 months).

MICA-TM and MICB C1_2\_A Genotyping {#Sec4}
-----------------------------------

MICA-TM and MICB C1_2\_A polymorphisms were genotyped in genomic DNA isolated from normal colonic mucosa and colorectal tumor tissue, respectively \[[@CR18]\]. Allele frequencies of MICA-TM and MICB C1_2\_A polymorphisms were compared to a group of 306 healthy control persons, analyzed previously (mean age, 62.8 ± 11.8 years; sampling period Jan. 1997 to Dec. 2000) \[[@CR17]\]. The MICA-TM polymorphism was analyzed by polymerase chain reaction (PCR) amplification with the primers 5′-CAGAGTCATTGGCAGACA-3′ (5′-Fam-labeled) and 5′-TTCTTCTTACAACAACGGAC-3′. The PCR products were separated by electrophoresis on denaturating 6% 0.3-mm polyacrylamide gels in the ALFexpress sequencer (Amersham Pharmacia, Uppsala, Sweden). The segregation of the MICA-TM alleles was controlled in 20 HLA-A, B, DR-typed families. Sequencing confirmed the allele size determined. As internal standards, a 73-bp PCR product from the transforming growth factor receptor II and ALFexpress Sizer 150 for MICB C1_2\_A were used, respectively.

MICB C1_2\_A alleles of interest, including the gold standards, were sequenced either directly as PCR products or after subcloning into the vector pCR2.1 (Invitrogen). For sequence analysis of MICB C1_2\_A microsatellite, alleles were amplified with the primers 5′-CCATAGTGTTTTCCATTGCAGGC-3′ and 5′-AGCCATGAGAAGCTATGTGGGG-3′. The PCR products were purified using a QIA Quick PCR Purification Kit (Qiagen, Hilden, Germany) and were sequenced using the ABI PRISM^TM^ dye terminator cycle sequencing kit on an ABI 373 DNA sequencer. The raw data were analyzed by the ABI Sequence Analysis program.

Screening for Tumor Microsatellite Instability and *KRAS* Oncogene Mutations {#Sec5}
----------------------------------------------------------------------------

Analysis of tumor microsatellite instability (MIN) was performed using the microsatellite markers BAT26, BAT40, *TGFBR2*(A)~10~, *BAX*(G)~8~, and the dinucleotide repeat *MFD15* (D17S250), with modifications according to the meeting report of the National Cancer Institute Workshop on microsatellite instability \[[@CR16]\]. Tumors exhibiting instability at 0--1 loci analyzed were considered as presenting low MIN and at ≥2 loci as high microsatellite instability (MIN-h).

Tumor DNA was screened for *KRAS* mutations in codon 12 (glycine, GGT) by primer-mediated restriction fragment length polymorphism (RFLP) analysis. The primers used were ACTGAATATAAACTTGTGGTAGTTGGA[C]{.ul}CT and TCATGAAAATGGTCAGAGAA, the underlined base within the forward primer introduces a *Bst*N I restriction site in the amplified wild-type sequence. The colon carcinoma cell line SW480 carrying a homozygous Val mutation at codon 12 was used as a positive control for RFLP analysis. Additionally, all tumor DNA samples displaying mutated *KRAS* sequences at codon 12 in RFLP analysis were further analyzed by sequencing in order to confirm to results of RFLP analysis and to determine which mutation was present. For sequence analysis, a 288-bp amplificate was generated using the primers ACTGGTGGAGTATTTGATAG and ACTCATGAAAATGGTCAGAG.

Statistical Analysis {#Sec6}
--------------------

Haplotype gene frequencies were determined by gene counting assuming homozygosity, if at a given locus only one allele could be identified. Correlations to histopathological parameters were performed comparing MICA-TM and MICB C1_2\_A alleles with tumor invasion, lymph node involvement, presence of distant metastasis, and UICC stages. Statistical significance for the two-point associations was tested by Chi-square calculation in the 2 × 2 table and Pearson′s coefficient, Fisher\'s exact test (two-sided) or phi coefficient was used, when appropriate. Survival times were calculated by Kaplan--Meier curves, and the log rank test was used for statistical analysis and comparison of different variables. For multivariate analysis, Cox regression analysis was performed using the Wald test for comparison of variables. A *p* value of less than 0.05 was used to indicate statistical significance. Statistical analysis was performed using the SPSS statistical software (SPSS version 11.5).

Results {#Sec7}
=======

MICA-TM and MICB C1_2\_A Allele Frequencies {#Sec8}
-------------------------------------------

Allele frequencies of MICA-TM and MICB C1_2\_A in colorectal cancer patients did not differ compared to a cohort of healthy control individuals (Table [I](#Tab1){ref-type="table"}). Homozygosity was most frequently observed in colorectal cancer patients for the MICA-TM A5.1 allele (*n* = 13; 16.4% of all patients) and for the MICB C1_2\_A CA15 allele (*n* = 4; 5.1% of all patients). Nonsignificant trends were observed in our cohort regarding an increased MICB C1_2\_A CA15 allele frequency (19.2% vs 10.5%) and a reduced CA17 allele frequency (11.4% vs 20.3%) in comparison to the control group. Table IAllele Frequencies (in %) of Microsatellites MICA-TM and MICB C1_2\_A in Colorectal Cancer Patients and Control Persons Colorectal cancer patients (*n* = 79)Controls (*n* = 306)MICA-TM allele A411.911.7 A510.613.6 A5.143.137.0 A621.922.4 A912.515.3MICB C1_2\_A allele CA1416.618.5 CA1519.210.5 CA16n.d.0.2 CA1711.420.3 CA188.37.2 CA193.1.1.1 CA203.74.1 CA218.08.9 CA224.37.2 CA235.65.9 CA2414.810.9 CA254.83.9 CA26n.d.0.8 CA27n.d.0.5Allele frequencies of control persons were reported in \[[@CR18]\]*n.d.* not detected in our patients\' cohort

Association of MICA-TM and MICB C1_2\_A Alleles with Tumor-Associated Variables {#Sec9}
-------------------------------------------------------------------------------

MICA-TM and MICB C1_2\_A alleles were investigated for possible correlation to various tumor-associated variables, including tumor invasion, lymph node involvement, presence of distant metastasis, UICC stages, microsatellite instability, and detection of *KRAS* mutations (codon 12). As shown in Table [II](#Tab2){ref-type="table"}, the MICA-TM A4 allele was associated with the presence of distant metastasis (*p* = 0.023). The presence of the MICA-TM A5 allele showed an inverse association to lymph node involvement (*p* = 0.015), presence of distant metastasis (*p* = 0.048), and advanced UICC stages (*p* = 0.003). The analysis of MICB C1_2\_A alleles showed an association of the CA14 allele with the presence of distant metastasis (*p* = 0.045) and of the CA21 allele with advanced UICC stages (*p* = 0.047). Table IIComparison of MICA-TM Allele Frequencies with Tumor-Associated Clinicopathological ParametersTumor classificationMICA-TM alleleA4A5A5.1A6A9Tumor invasion T1/23/173/1712/177/173/17 T3/411/448/4432/4418/4411/44Lymph node involvement N09/5111/5139/5120/5111/51 N1-35/100/10^a^6/105/103/10Distant metastasis M08/4712/4735/4717/4711/47 M110/23^b^1/23^c^14/2311/233/23UICC stages UICC I/II4/3010/3022/3011/305/30 UICC III/IV14/392/39^d^26/3917/399/39^a^*p* \< 0.05^b^*p* \< 0.023^c^*p* \< 0.048^d^*p* \< 0.02

MICA-TM and MICB C1_2\_A Allele Distribution, Microsatellite Instability, and *KRAS* Mutations {#Sec10}
----------------------------------------------------------------------------------------------

A trend for an increased frequency of the MICB C1_2\_A CA21 allele was observed in patients with colorectal tumors showing high microsatellite instability as defined by different lengths of PCR products in more than two markers (*p* = 0.047; Table [III](#Tab3){ref-type="table"}). Mutations in the *KRAS* oncogene were detected in 17 colorectal cancer samples (20.9%). The *KRAS* codon 12 mutation in tumor DNA samples were determined by sequencing the PCR-generated fragment, and the following mutations (12C: *n* = 3; 12D: *n* = 4; 12 V: *n* = 7; 12 S: *n* = 2) were detected. No correlation of MICA-TM alleles with the presence of *KRAS* mutations was seen in the investigated colorectal cancer patients. For MICB C1_2\_A alleles, only a trend toward an association with *KRAS* mutations was observed for the CA 23 allele (*p* = 0.087). Table IIIMICA-TM and MICB C1_2\_A Polymorphisms in Colorectal Cancer Patients with Regard to Tumor Microsatellite Stability or *KRAS* Codon 12 MutationsMICA-TM/MICB C1_2\_ATumor-related parametersAllele frequenciesMIN (*n* = 17)MIN-h (*n* = 10)*KRAS* mutations (*n* = 17)MICA-TM allele A46/214/214/21 A53/143/143/14 A5.110/567/569/56 A66/323/329/32 A94/162/165/16MICB C1_2\_A allele CA147/243/243/24 CA154/283/284/28 CA16n.d.n.d.n.d. CA172/171/173/17 CA182/111/113/11 CA191/51/51/5 CA201/60/61/6 CA215/134/13\*4/13 CA222/71/73/7 CA231/90/94/9 CA244/244/244/24 CA251/60/63/6 CA26n.d.n.d.n.d. CA27n.d.n.d.n.d.Microsatellite instability (MIN) was defined as altered lengths of PCR products typing five defined mono- and dinucleotide repeat markers. Tumor MIN was considered when at least one repeat locus showed altered length and high microsatellite instability (MIN-h) when two or more microsatellite markers showed tumor DNA replication errors. For analysis, only MICA-TM and MICB C1_2\_A allele frequencies \>5% were considered\**p* = 0.047

Analysis of Survival Times {#Sec11}
--------------------------

Overall survival was analyzed in 61 patients with sporadic colorectal carcinomas, followed and documented prospectively in an institutional data base. Tumor-related postoperative survival was 86.0 ± 4.4 months for patients following complete tumor resection (R0-status; *n* = 45) and 29.8 ± 8.4 months for patients with tumor infiltrated resection margins or remaining distant metastasis (*n* = 25; *p* \< 0.001). Survival in the study cohort was related to classical parameters of tumor progression like lymph node involvement (*p* = 0.005) and UICC stages (*p* = 0.001) according to univariate analysis, as shown in Table [IV](#Tab4){ref-type="table"}. Further analysis indicated significantly shorter survival times in patients positive for the MICA-TM A4 allele (negative vs positive, 80.6 vs 51.9 months; *p* = 0.015, Fig. [1](#Fig1){ref-type="fig"}). Estimated 5-year survival times were 75% and 43% for MICA-TM A4 negative and positive patients, respectively. Multivariate analysis using the Cox regression model after exclusion of the variable metastatic disease indicated that presence of MICA-TM A4 allele (HR, 2.71; 95% CI, 1.13--6.49; *p* = 0.025) and the tumor-related nodal status (HR, 3.99; 95% CI, 1.61--9.86; *p* = 0.003) were independent prognostic variables. Table IVSurvival of Colorectal Cancer PatientsTumor-related parametersSurvival times (mean ± SD; months)(95% Confidence interval)*p* valueTumor invasion T1/2 (*n* = 13)85.0 ± 9.6(66.2--103.9)0.113 T3/4 (*n* = 48)69.0 ± 6.0(57.1--80.8)Lymph node involvement N0 (*n* = 34)88.8 ± 5.4(78.1--99.4)0.005 N1 (*n* = 18)65.3 ± 8.9(47.7--82.8) N2 (*n* = 9)25.9 ± 5.2(6.9--44.9)UICC stages UICC I/II (*n* = 30)93.9 ± 4.8(84.4--103.4) UICC III/IV (*n* = 31)52.7 ± 7.3(38.3--67.0)\<0.001A4 No (*n* = 47)80.6 ± 5.6(69.7--91.6) Yes (*n* = 14)51.9 ± 10.9(30.5--73.2)0.015A5 No (*n* = 47)56.0 ± 6.1(56.0--80.2) Yes (*n* = 14)87.4 ± 6.3(75.0--99.7)0.074A5.1 No (*n* = 19)65.2 ± 9.8(45.9--84.5) Yes (*n* = 42)75.2 ± 5.7(63.9--86.6)0.257A9 No (*n* = 48)75.9 ± 5.5(65.0--86.8) Yes (*n* = 13)59.5 ± 10.6(38.7--80.3)0.106CA24 No (*n* = 42)66.7 ± 6.1(54.7--78.7) Yes (*n* = 19)84.3 ± 8.6(67.4--101.3)0.108Microsatellite instability (≥1 marker) No (*n* = 54)71.7 ± 5.7(60.4--83.0) Yes (*n* = 7)82.2 ± 9.5(63.6--100.9)0.410*KRAS* codon 12 mutations No (*n* = 44)78.7 ± 6.0(66.9--90.4) Yes (*n* = 17)58.7 ± 9.5(40.0--77.5)0.093Univariate analysis of tumor-related survival times of patients with indicated clinicopathological parameters and selected MICA-TM (A4, A5, A5.1, A9) and MICB C1_2\_A (CA24) alleles in patients with colorectal cancer (*n* = 61). Kaplan--Meier analysis and the log rank test were used for comparisons and statistical evaluationFig. 1Survival analysis in relation to MICA-TM A4 allele haplotype. Kaplan--Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with colorectal cancer. *Short vertical lines* indicate censored observations for comparison of patients without (*n* = 46) and with MICA-TM A4 allele (*n* = 15, *p* = 0.015)

Survival Analysis in Microsatellite Stable Tumors {#Sec12}
-------------------------------------------------

We have further analyzed survival times in patients with microsatellite stable tumors (*n* = 54). As shown in Fig. [2](#Fig2){ref-type="fig"}, prognostic relevance of MICA-TM A4 was even more evident in microsatellite stable tumors (*p* = 0.006) in comparison to the other known prognostic variables such as lymph node involvement (*p* = 0.001) and UICC classification (*p* \< 0.001, Table [IV](#Tab4){ref-type="table"}). In addition, MICA-TM A9 was associated with reduced survival times (*p* = 0.034) in microsatellite stable colorectal cancer patients, while the MICA-TM A5 was inversely associated with a better prognosis (*p* = 0.042), providing evidence for a tumor suppressive effect of the MICA-TM A5 allele (Table [V](#Tab5){ref-type="table"}). Further combined analysis of colorectal cancer patients with MICA-TM alleles positive for either A4 or A9 vs patients negative for both A4 and A9 alleles had markedly reduced survival times, as shown in Fig. [3](#Fig3){ref-type="fig"} (*p* \< 0.001), with an estimated 5-year survival of 36% vs 85%, respectively. Multivariate analysis by Cox regression with inclusion of the variables MICA-TM A4, A5, A9, lymph node involvement, UICC stages, metastatic disease, and MICA-TM A4 or A9 positive indicated that metastatic disease (HR, 4.43; 95% CI, 1.66--11.81; *p* = 0.003), lymph node involvement (HR, 3.27; 95% CI, 1.14--9.30; *p* = 0.026) and MICA-TM A4 or A9 positive (HR, 4.02; 95% CI, 1.29--12.56; *p* = 0.016) were of independent prognostic relevance in patients with microsatellite stable colorectal tumors. Fig. 2MICA-TM A4 allele detection in microsatellite stable colorectal cancer patients. Kaplan--Meier analysis of tumor-related survival times in association with MICA-TM A4 allele in patients with microsatellite stable colorectal cancer. *Vertical lines* indicate censored observations for comparison of patients without (*n* = 42) and with MICA-TM A4 allele (*n* = 12, *p* = 0.006). The estimated 5-year survival rate was 72% vs 38%, respectivelyTable VSurvival of Patients with Microsatellite Stable Colorectal CancerTumor-related parametersSurvival times (mean ± SD; months)(95% Confidence interval)*p* valueTumor invasion T1/2 (*n* = 12)81.8 ± 11.4(59.5--104.2)0.209 T3/4 (*n* = 42)67.4 ± 5.8(54.5--80.3)Lymph node involvement N negative (*n* = 28)89.9 ± 6.0(78.1--101.7)0.001 N positive (*n* = 26)48.6 ± 7.9(33.1--64.1)UICC stages UICC I/II (*n* = 24)96.7 ± 4.9(87.0--106.4)\<0.001 UICC III/IV (*n* = 30)50.8 ± 7.3(36.4--65.23)Distant metastasis M0 (*n* = 38)86.7 ± 5.4(76.0--97.4)\<0.001 M1 (*n* = 16)38.0 ± 9.5(19.4--65.7)A4 No (*n* = 42)79.1 ± 6.0(67.2--91.0)0.006 Yes (*n* = 12)46.4 ± 12.1(22.5--70.3)A5 No (*n* = 42)65.3 ± 6.6(52.4--78.3)0.042 Yes (*n* = 12)88.4 ± 7.1(74.3--102.5)A5.1 No (*n* = 16)62.7 ± 10.89(41.4--84.1)0.236 Yes (*n* = 38)73.3 ± 6.3(60.9--85.8)A9 No (*n* = 43)75.7 ± 6.0(63.8--87.6)0.034 Yes (*n* = 11)51.4 ± 10.9(30.0--72.8)CA24 No (*n* = 37)64.8 ± 6.6(51.7--77.9)0.156 Yes (*n* = 11)81.9 ± 9.5(63.2--100.6)*KRAS* codon 12 mutations No (*n* = 39)77.2 ± 6.5(64.4--90.0)0.121 Yes (*n* = 15)54.5 ± 10.5(33.9--75.1)Univariate analysis of tumor-related survival times of patients with microsatellite stable (MIN negative) colorectal cancer and selected MICA-TM (A4, A5, A5,1, A9) and MICB C1_2\_A (CA24) alleles in association with indicated clinicopathological parameters (*n* = 54). Kaplan--Meier analysis and the log rank test were used for comparisons and statistical evaluationFig. 3MICA-TM A4 or A9 haplotype in microsatellite stable colorectal cancer patients. Kaplan--Meier analysis of tumor-related survival times in association with MICA-TM A4 or A9 alleles in patients with microsatellite stable colorectal cancer. *Vertical lines* indicate censored observations for comparison of patients either positive for MICA-TM A4 or A9 alleles (*n* = 23) in comparison to patients without MICA-TM A4 and A9 alleles (*n* = 31, *p* ≤ 0.001)

Conclusions {#Sec13}
===========

The NK group 2, member D -NKG2D protein, is an activating cell surface receptor expressed on NK cells and on some T-cell subsets \[[@CR19], [@CR20]\]. Ligands of human NKG2D include MICA, MICB, UL-16-binding proteins, and Letal and are expressed on several tumors, especially on epithelium-derived cancer cells \[[@CR4]\]. Ligand binding of MICA and MICB to the NKG2D receptor mediates innate antitumor response by stimulation of NK cells and gamma delta T cells and may modulate CD8aß T-cell responses \[[@CR21], [@CR22]\]. It was shown that tumor cells expressing high levels of MICA and NKG2D ligands were rejected by NK cells and CD8 alpha/beta T cells and stimulated antitumor activity in a mouse model \[[@CR23], [@CR24]\]. Analysis of the structure of the NKG2D-MICA complex by protein expression, crystallization, and crystallography showed the interaction of a NKG2D homodimer with a single MICA monomer either at the alpha 1 or alpha 2 domain forming a relatively stable Interaction, more stable than other T-cell receptor--ligand or other NK cell surface receptor--ligand complexes \[[@CR25]\]. Groh et al. have shown an increased tumor antigen cross-presentation and priming of antitumor CD8 and CD4 T-cell responses by loading of dendritic cells with MICA antibodies following coculture with various tumor cells \[[@CR21]\]. Recent studies investigating mRNA expression on various benign and malignant tissues and samples from patients with autoimmune diseases have shown a more widely distribution of MICA and MICB expression independent of malignancies or inflammation with the only exception for the central nervous system \[[@CR26]\]. So far, it remains unclear whether a different genomic composition of MICA alleles might alter the ligand affinity of MICA alleles to NKG2D receptors and thereby modulate the host antitumor response.

In our study, we observed a significant association of MICA-TM A4 allele with advanced tumor progression and reduced tumor-related survival times. In contrast, patients with the MICA-TM A5 allele had a remarkably low rate of tumor lymph node invasion and less distant metastases. Furthermore, in microsatellite stable tumors, genomic MICA-TM A4 and A9 alleles were related to advanced tumor progression and shorter tumor-related survival, while the MICA-TM A5 allele was again found to have a tumor suppressive effect. These findings first indicate a host imminent predisposition with an altered tumor immune surveillance probably mediated by a differential composition of host MICA-TM alleles in patients with colorectal cancer.

At present, the there is no evidence that the MICA-TM microsatellite polymorphism directly affects NKG2D interaction or shedding of MICA molecules. Interestingly, the MICA-TM A4 and A9 alleles share methionine, M, at amino acid position 129, whereas the A5 alleles always code for valine, V, at this position (IMGT/HLA Database). The MICA-TM alleles 5.1 and 6 do not form a haplogroup with this polymorphic residue and can possess either M or V at amino acid position 129. Steinle et al. \[[@CR5]\] have shown that MICA V129 is associated with reduced affinity for NKG2D, whereas M129 confers high NKG2D binding affinity to NKG2D receptors involving the amino acid position M129 might be responsible for the described association with advanced tumor progression and reduced tumor-related survival time. Thus, shedded MICA M129 might more powerfully impair NK and CD8 T-cell responses in vivo and/or downregulate NKG2D expression on effector cells. But, surface MICA M129 might also directly control its pronounced downregulation upon interaction with a strong-affinity MICA protein.

In other epithelial tumors, Lo et al. have described an association of the MICA-TM A9 allele with gastric cancer and a less schirrous phenotype \[[@CR27]\]. The relevance of the NKG2D-ligand immune response in gastric cancer is further supported by Osaki et al. describing a decreased NKG2D expression on CD8+ T cell in patients with gastric cancer \[[@CR28]\]. Busche et al. have shown a reduced staining of MICA on the surface of lung cancer samples \[[@CR29]\]. In addition, the authors demonstrated in an experimental human lung cancer therapy model that an upregulation of MICA expression in lung cancer cells by adenoviral transfection of expression plasmids was able to reestablish the previously decreased NK cell-mediated antitumor immunity. In thyroid carcinomas, MICA and MICB expression was detected by immunohistochemistry on most tumor samples and on thyroid cancer cell lines with a correlation of their sensitivity to killing by NKG2D-positive NK cells. Transient transfection of mutant BRAF and *KRAS* oncogenes led to increased MICA and MICB expression in thyroid cancer cells \[[@CR30]\]. As shown in our analysis, we only observed a trend for an association of the MICB C1_2\_A CA23 allele (*p* = 0.087) with the detection of *KRAS* mutations in colorectal cancer samples.

Differential expression of MICA molecules locally present at the surface of tumor cells might additionally regulate local tumor--immune interactions. We therefore cannot rule out that alterations of MICA or MICB at the level of transcription or protein synthesis might result in different levels of MICA and MICB protein expression on the surface of tumor cells. Therefore, the investigation of MICA and MICB alleles at protein expression level on the individual tumor samples will be of further interest. Several studies using immunohistochemistry have shown a reduced expression of MICA at the protein level on tumor cells \[[@CR27], [@CR29]\]. It is unclear whether the reduction in MICA protein expression on tumor cells is caused by reduced MICA synthesis or is the result of an increased shedding of MICA molecules in cancer patients.

The factors involved in shedding of soluble MICA molecules from tumor cells are only poorly understood. It is assumed that metalloproteinases are involved in proteolytic cleavage of soluble MICA molecules from the surface of tumor cells, leading to inactivation of NKG2D mediated antitumor response \[[@CR31]\]. Elevated levels of soluble MICA levels were described for patients with gastrointestinal cancer \[[@CR9]\]. Interestingly, the authors also report an association of MICA levels with advanced staged of tumor progression especially in patients with gastrointestinal renal, prostate, and breast cancer with highest levels in patients with metastatic disease. It is assumed that the reduction of MICA expression by release and shedding from the cell surface would potentially reduce the immunogenetic signals of tumor cells becoming less detectable for NK and T cells. These findings further support the concept that the NKG2D/ligand system seems to play an important role in the immune surveillance of tumor cells. However, it remains to be determined if any of the described MICA alleles might be related to differential shedding of soluble MICA molecules and thereby influence antitumor immunity and tumor progression.

Elevated antibodies against MICA were recently described in tumor patients and in recipients of renal and heart transplants with differential responses to immune therapy or an increased rejection rate associated with a reduced graft survival \[[@CR32]--[@CR34]\]. It is assumed that MICA antibodies are able to opsonize cancer cells for presentation to dendritic cells and induce tumor cell lysis through complement fixation. In addition, genetic modifications of human T cells with chimeric NKG2D receptors might further increase innate antitumor response \[[@CR35]\].

In summary, these findings might indicate a host innate immunogenetic antitumor surveillance associated with advanced colorectal tumor progression and reduced tumor-related survival based on the presence of specific MICA-TM alleles involved in NKG2D-receptor activation.
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